Personalized FGF21 Secretion Promotion Systems and Methods

The present inventive concept discloses a next-generation approach to promoting FGF21 secretion, leveraging advanced technologies such as microbiome analysis, machine learning, and wearable devices to provide personalized, real-time, and optimized FGF21 secretion promotion.

The original patent relates to a composition for promoting the secretion of fibroblast growth factor 21 (FGF21) using Bifidobacterium breve M-16V. However, this approach has limitations, including the lack of personalization and real-time monitoring capabilities. The present inventive concept addresses these limitations by introducing a system that can identify a subject's specific gut microbiome, select the most effective Bifidobacterium bacterium strain, and create a customized composition for promoting FGF21 secretion.

The inventive concept comprises a microbiome analyzer, a Bifidobacterium bacterium strain selector, and a personalized probiotic composition generator. The microbiome analyzer identifies the subject's specific gut microbiome, and the strain selector selects the most effective Bifidobacterium bacterium strain based on the subject's gut microbiome. The personalized probiotic composition generator then creates a customized composition for promoting FGF21 secretion. Additionally, the inventive concept includes a wearable device for real-time monitoring of FGF21 levels in the subject's serum. The system can also utilize machine learning algorithms to predict optimal Bifidobacterium bacterium strains for FGF21 secretion promotion based on a subject's genetic profile, medical history, and lifestyle factors.

The present inventive concept introduces several novel and non-obvious features, including the use of microbiome analysis, machine learning, and wearable devices to provide personalized and real-time FGF21 secretion promotion. The inventive concept's ability to tailor the FGF21 secretion promoter to a subject's specific health needs and genetic predispositions is also a significant departure from the original patent.

Alternative embodiments of the inventive concept may include the use of different types of microbiome analyzers, such as those based on machine learning or genomics. Additionally, the system may be adapted for use in different populations, such as pediatric or geriatric populations. The inventive concept may also be integrated with other health monitoring systems, such as electronic health records or mobile health applications.

The present inventive concept has significant commercial potential in the personalized medicine and healthcare industries. The ability to provide personalized, real-time, and optimized FGF21 secretion promotion may lead to improved health outcomes and reduced healthcare costs. The inventive concept may also be licensed to pharmaceutical companies, biotech companies, or healthcare providers, generating revenue through royalties or partnerships.